Innovations in Corneal Crosslinking.
CXL
PRK
customized
oxygen
riboflavin
transepithelial
Journal
Current eye research
ISSN: 1460-2202
Titre abrégé: Curr Eye Res
Pays: England
ID NLM: 8104312
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
pubmed:
3
12
2022
medline:
9
2
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
Corneal Crosslinking (CXL) strengthens the keratoconus cornea and prevents further disease progression. Modified crosslinking protocols and different riboflavin solutions have been proposed to optimize the procedure and improve treatment success. PubMed research of relevant publications and report of own experiences with different CXL protocols. Accelerated CXL shows comparable efficiency with shorter surgery time and similar complication rates. Customized CXL provides improved results with faster epithelial healing. CXL in a hyperoxic environment seems to be a safe and effective transepithelial alternative with presumably less complications and fewer side effects. Thin corneas (<400 µm) can be treated safely by corneal swelling using hypoosmolar riboflavin solutions and reducing the applied UV-energy. The combination of CXL with photorefractive keratectomy (PRK) can be considered in patients with contact lens intolerance improving visual acuity, however, with increased risk of visual loss compared to CXL alone. Two-Photon (2Ph) CXL is a promising new technology enabling three-dimensional CXL. Recently developed CXL protocols offer advantages over the standard "Dresden-protocol" and should be considered in patients with progressive keratectasia.
Identifiants
pubmed: 36458595
doi: 10.1080/02713683.2022.2146725
doi:
Substances chimiques
Photosensitizing Agents
0
Riboflavin
TLM2976OFR
Cross-Linking Reagents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM